Evidence-Based Medical News

Mode

All Oncology Infectious Disease Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Primary Care & Family Medicine Gastroenterology Nutrition & Obesity Medicine Orthopedics & Sports Medicine OB/GYN & Women's Health Radiology & Imaging Anesthesiology & Pain Medicine Genetics & Precision Medicine Pulmonology & Critical Care Physical Medicine & Rehab Urology Nephrology Emergency Medicine Ophthalmology Dermatology Hematology Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Text Size

Log in / Sign up

Metastatic Prostate Cancer

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Metastatic Prostate Cancer

33 trials tracked for Metastatic Prostate Cancer: 7 in phase 3 or 4 and 4 with published results. The most-cited published study has 335 citations.

33Trials tracked

7Phase 3 & 4

0Recruiting

4With published results

Phase distribution

Phase 4 1 Phase 3 6 Phase 2 21 Phase 1 2 Other / NA 3

Phase 3 Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer Completed · 335 cited
Phase 3 A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer Completed · 289 cited
Phase 4 Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent Completed · 64 cited
Phase 3 Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer Completed
Phase 3 Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer Completed
Phase 3 TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer Completed

Show 27 more trials

Phase 3 Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate Completed
Phase 2 68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa) Completed
Phase 2 Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer Completed
Phase 2 Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects Completed
Phase 2 A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer Completed
Phase 2 Phase II Sunitinib Prog Met AIPC Completed
Phase 2 ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer Completed
Phase 2 I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW). Completed
Phase 2 Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer Completed
Phase 2 Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer Completed
Phase 2 COMbination of Bipolar Androgen Therapy and Nivolumab Completed
Phase 2 The Role of 68Gallium PSMA-11 in Enhancing Diagnosis of Primary and Metastatic Prostate Cancer Completed
Phase 2 EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer Completed
Phase 2 Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Completed
Phase 2 Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer Completed
Phase 2 Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer Completed
Phase 2 Evaluation of 18F-DCFBC PSMA-based PET Imaging for Detection of Metastatic Prostate Cancer Completed
Phase 2 Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence Completed
Phase 2 Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations Completed
Phase 2 A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer Completed
Phase 2 One-year, Open Extension to Evaluate the Treatment of Patients With Castration-Resistant Prostate Cancer With YONSA™ Completed
Phase 2 A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer Completed
Phase 1 PSMA-PET/MRI for Radiation Treatment Planning in Patients With Locally Metastatic Prostate Cancer: A Pilot Study Completed
Phase 1 Trial of ARV-110 and Abiraterone in Participants With Metastatic Prostate Cancer Completed
N/A PRAGMA (Prostate Radio Ablation Guided by Magnetic Resonance Imaging Acquisition) in Metastatic Prostate Cancer Completed
N/A MSG Use With 18F-DCFPyL PET/CT Imaging Completed
N/A PROState Pathway Embedded Comparative Trial Completed

Showing the 33 most-cited and recently-updated of 33 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Metastatic Prostate Cancer: what the trials found

Cabazitaxel demonstrated significant improvements in radiographic progression-free survival (rPFS), progression-free survival (PFS), and overall survival (OS) compared to standard treatments ².

Triptorelin pamoate (embonate) salt achieved a 99.5% success rate in reaching castrate levels of serum testosterone by day 29, with 100% maintenance through week 24, and resulted in a reduction of PSA by approximately 90-92% at weeks 12 and 24 ⁵.

TAVT-45 successfully achieved castrate levels of serum testosterone (approximately 1.0 ng/dL) across multiple evaluation groups ⁶.

PROSTVAC-V showed no statistically significant difference in overall survival compared to other arms ⁴.

Recent results — preliminary, needs further review

I-131-1095 showed a significantly higher PSA response rate (44% vs 10%) but did not show a statistically significant difference in objective response rate or radiographic progression-free survival ⁹.
Bavdegalutamide showed a 48.9% rate of patients without PSA progression ¹.

For the clinician treating this condition

Cabazitaxel is associated with statistically significant improvements in rPFS, PFS, and OS ².
Triptorelin pamoate and TAVT-45 are effective for achieving and maintaining castrate levels of serum testosterone [5, 6].
PROSTVAC-V did not demonstrate a statistically significant impact on overall survival ⁴.

AI synthesis of 6 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.